Given the significant role of the SWI/SNF complex in melanoma, future therapeutic approaches must focus on mechanisms of synergic effect and synthetic lethality to enhance the therapeutic benefits of inhibitors, particularly when there is a deficiency in the functional domains mentioned above. Here, SMARCA1 is linked to melanoma.